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More than 25% of the U.S. population aged 65 years has diabetes mellitus (hereafter referred
to as diabetes),1 and the aging of the overall population is
a significant driver of the diabetes epidemic. Although the
burden of diabetes is often described in terms of its impact
on working-age adults, diabetes in older adults is linked to
higher mortality, reduced functional status, and increased
risk of institutionalization.2 Older adults with diabetes are
at substantial risk for both acute and chronic microvascu-
lar and cardiovascular complications of the disease.
Despite having the highest prevalence of diabetes of
any age-group, older persons and/or those with multiple
comorbidities have often been excluded from randomized
controlled trials of treatments—and treatment targets—
for diabetes and its associated conditions. Heterogeneity
of health status of older adults (even within an age
range) and the dearth of evidence from clinical trials
present challenges to determining standard intervention
strategies that fit all older adults. To address these issues,
the American Diabetes Association (ADA) convened a
Consensus Development Conference on Diabetes and
Older Adults (defined as those aged  65 years) in Feb-
ruary 2012. Following a series of scientific presentations
by experts in the field, the writing group independently
developed this consensus report to address the following
questions:
1 What is the epidemiology and pathogenesis of diabetes
in older adults?
2 What is the evidence for preventing and treating diabe-
tes and its common comorbidities in older adults?
3 What current guidelines exist for treating diabetes in
older adults?
4 What issues need to be considered in individualizing
treatment recommendations for older adults?
5 What are consensus recommendations for treating older
adults with or at risk for diabetes?
6 How can gaps in the evidence best be filled?
WHAT IS THE EPIDEMIOLOGY AND
PATHOGENESIS OF DIABETES IN OLDER
ADULTS?
According to the most recent surveillance data, the preva-
lence of diabetes among U.S. adults aged  65 years var-
ies from 22 to 33%, depending on the diagnostic criteria
used. Postprandial hyperglycemia is a prominent character-
istic of type 2 diabetes in older adults,3,4 contributing to
observed differences in prevalence depending on which
diagnostic test is used.5 Using the hemoglobin A1C (A1C)
or fasting plasma glucose (FPG) diagnostic criteria, as is
currently done for national surveillance, one-third of older
adults with diabetes are undiagnosed.1
The epidemic of type 2 diabetes is clearly linked to
increasing rates of overweight and obesity in the U.S. pop-
ulation, but projections by the Centers for Disease Control
and Prevention (CDC) suggest that even if diabetes inci-
dence rates level off, the prevalence of diabetes will double
in the next 20 years, in part due to the aging of the popu-
lation.6 Other projections suggest that the number of cases
of diagnosed diabetes in those aged  65 years will
increase by 4.5-fold (compared to 3-fold in the total
population) between 2005 and 2050.7
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The incidence of diabetes increases with age until
about age 65 years, after which both incidence and preva-
lence seem to level off (www.cdc.gov/diabetes/statistics).
As a result, older adults with diabetes may either have
incident disease (diagnosed at and after age 65 years) or
long-standing diabetes with onset in middle age or earlier.
Demographic and clinical characteristics of these two groups
differ in a number of ways, adding to the complexity of
making generalized treatment recommendations for older
patients with diabetes. Older-age–onset diabetes is more
common in non-Hispanic whites and is characterized by
lower mean A1C and lower likelihood of insulin use than is
middle-age–onset diabetes. Although a history of retinopathy
is significantly more common in older adults with middle-
age–onset diabetes than those with older-age onset, there is,
interestingly, no difference in prevalence of cardiovascular
disease (CVD) or peripheral neuropathy by age of onset.8
Older adults with diabetes have the highest rates of
major lower-extremity amputation,9 myocardial infarction
(MI), visual impairment, and end-stage renal disease of
any age-group. Those aged  75 years have higher rates
than those aged 65–74 years for most complications.
Deaths from hyperglycemic crises also are significantly
higher in older adults (although rates have declined mark-
edly in the past 2 decades). Those aged  75 years also
have double the rate of emergency department visits for
hypoglycemia than the general population with diabetes.10
Although increasing numbers of individuals with type 1
diabetes are living into old age,11 this discussion of patho-
physiology concerns type 2 diabetes—overwhelmingly the
most common incident and prevalent type in older age-
groups. Older adults are at high risk for the development of
type 2 diabetes due to the combined effects of increasing
insulin resistance and impaired pancreatic islet function with
aging. Age-related insulin resistance appears to be primarily
associated with adiposity, sarcopenia, and physical inactiv-
ity,12 which may partially explain the disproportionate
success of the intensive lifestyle intervention in older
participants in the Diabetes Prevention Program (DPP).13
However, age-related declines of pancreatic islet function4,14
and islet proliferative capacity15,16 have previously been
described.
WHAT IS THE EVIDENCE FOR PREVENTING
AND TREATING DIABETES AND ITS COMMON
COMORBIDITIES IN OLDER ADULTS?
Screening for Diabetes and Prediabetes
Older adults are at high risk for both diabetes and prediabe-
tes, with surveillance data suggesting that half of older adults
have the latter.1 The ADA recommends that overweight
adults with risk factors—and all adults aged  45 years—be
screened in the clinical setting every 1–3 years using either an
FPG test, A1C, or oral glucose tolerance test. The recommen-
dations are based on substantial indirect evidence for the
benefits of early treatment of type 2 diabetes, the fact that
type 2 diabetes is typically present for years before clinical
diagnosis, and the evidence that signs of complications are
prevalent in “newly diagnosed” patients.17
The benefits of identification of prediabetes and asymp-
tomatic type 2 diabetes in older adults depend on whether
primary or secondary preventive interventions would likely
be effective and on the anticipated timeframe of the benefit
of interventions versus the patient’s life expectancy. Most
would agree that a functional and generally healthy 66-year-
old individual should be offered diabetes screening since
interventions to prevent type 2 diabetes or the complications
of type 2 diabetes would likely be beneficial given the pre-
sumption of decades of remaining life. Most would also
agree that finding prediabetes or early type 2 diabetes in a
95-year-old individual with advanced dementia would be
unlikely to provide benefit.
Prevention or Delay of Type 2 Diabetes
Numerous clinical trials have shown that in high-risk sub-
jects (particularly those with impaired glucose tolerance),
type 2 diabetes can be prevented or delayed by lifestyle
interventions or by various classes of medications. These
trials primarily enrolled middle-aged participants. In the
DPP, which is the largest trial to date, ~ 20% of partici-
pants were aged  60 years at enrollment. These partici-
pants seemed to have more efficacy from the lifestyle
intervention than younger participants, but did not appear
to benefit from metformin.13,18 Follow-up of the DPP cohort
for 10 years after randomization showed ongoing greater
impact of the original lifestyle intervention in older partici-
pants (49% risk reduction in those aged  60 years at ran-
domization vs 34% for the total cohort)19 and additional
benefits of the lifestyle intervention that might impact older
adults, such as reduction in urinary incontinence,20
improvement in several quality-of-life domains,21 and
improvements in cardiovascular risk factors.22 Although
these results suggest that diabetes prevention through life-
style intervention be pursued in relatively healthy older
adults, the DPP did not enroll significant numbers
aged > 70 years or those with functional or cognitive
impairments. Preventive strategies that can be efficiently
implemented in clinical settings and in the community have
been developed and evaluated,23 but as yet there has been
little focus on older adults in these translational studies.
Interventions to Treat Diabetes
Glycemic Control
A limited number of randomized clinical trials in type 2
diabetes form the basis of our current understanding of the
effects of glucose lowering on microvascular complica-
tions, cardiovascular complications, and mortality. While
these trials have provided invaluable data and insights,
they were not designed to evaluate the health effects of
glucose control in patients aged  75 years or in older
adults with poor health status. There are essentially no
directly applicable clinical trial data on glucose control for
large segments of the older diabetic patient population.
The UK Prospective Diabetes Study (UKPDS), which
provided valuable evidence of the benefits of glycemic con-
trol on microvascular complications, enrolled middle-aged
patients with newly diagnosed type 2 diabetes, excluding
those aged  65 years at the time of enrollment.24,25
Microvascular benefits persisted during the post-trial fol-
low-up period, and statistically significant reductions in
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both mortality and MIs emerged, referred to as the “legacy
effect” of early glycemic control.26
After the publication of the main UKPDS results, three
major randomized controlled trials (the Action to Control
Cardiovascular Risk in Diabetes [ACCORD] trial, the
Action in Diabetes and Vascular Disease: Preterax and
Diamicron MR Controlled Evaluation [ADVANCE] trial,
and the Veterans Affairs Diabetes Trial [VADT]) were
designed to specifically examine the role of glycemic con-
trol in preventing CVD events in middle-aged and older
patients with type 2 diabetes. The trials enrolled patients
at significantly higher cardiovascular risk than did the
UKPDS, with each having a substantial proportion of
participants with a prior cardiovascular event, mean age at
enrollment in the 60s, and established diabetes (8–11 years).
Each of these trials aimed, in the intensive glycemic
control arm, to reduce glucose levels to near-normal levels
(A1C <6.0 or <6.5%).
The glucose control portion of the ACCORD trial was
terminated after approximately 3 years because of exces-
sive deaths in the intensive glucose control arm.27 The pri-
mary combined outcome of MI, stroke, and cardiovascular
death was not significantly reduced. Prespecified subgroup
analyses suggested that the disproportionate cardiovascular
mortality risk in the intensive glycemic control group was
in participants under the age of 65 years as opposed to
older participants. However, hypoglycemia and other
adverse effects of treatment were more common in older
participants.28
The ADVANCE trial did not demonstrate excessive
deaths attributable to intensive glucose control during a
median follow-up of 5 years. While there were no statisti-
cally significant cardiovascular benefits, there was a signifi-
cant reduction in the incidence of nephropathy. In
prespecified subgroup analysis of age < or 65 years,
there was no difference between age-groups for the
primary outcome.29
Over 5 years of follow-up, the VADT found no statis-
tically significant effect of intensive glucose control on
major cardiovascular events or death, but it did find signif-
icant reductions in onset and progression of albuminuria.30
The trial did not have prespecified subgroup analyses by
age. Post hoc analyses suggested that mortality in the
intensive versus standard glycemic control arm was related
to duration of diabetes at the time of study enrollment.
Those with diabetes duration less than 15 years had a
mortality benefit in the intensive arm, while those with
duration of 20 years or more had higher mortality in the
intensive arm.31
These three trials add to the uncertainty regarding the
benefits and risks of more intensive treatment of hypergly-
cemia in older adults. An ADA position statement sur-
mised that the combination of the UKPDS follow-up study
and subset analyses of the later trials “… suggest the
hypothesis that patients with shorter duration of type 2
diabetes and without established atherosclerosis might
reap cardiovascular benefit from intensive glycemic con-
trol, [while] … potential risks of intensive glycemic control
may outweigh its benefits in other patients, such as those
with a very long duration of diabetes, known history of
severe hypoglycemia, advanced atherosclerosis, and
advanced age/frailty.”32
Recently, a Japanese trial reported results of a multi-
factorial intervention versus standard care in about 1,000
patients aged 65 years (mean age 72 years). After
6 years, no differences in mortality or cardiovascular
events were found, but the intervention’s effect on glyce-
mia was minimal and the number of events was low.33
Since randomized controlled trials have not included
many older patients typical of those in general practice, it
is instructive to observe the relationship between glycemic
control and complications in general populations of older
diabetic patients. A study from the U.K. General Practice
Research Database showed that for type 2 diabetic
patients aged  50 years (mean age 64 years) whose
treatment was intensified from oral monotherapy to addi-
tion of other oral agents or insulin, there was a U-shaped
association between A1C and mortality, with the lowest
hazard ratio for death at an A1C of about 7.5%. Low
and high mean A1C values were associated with
increased all-cause mortality and cardiac events.34 A ret-
rospective cohort study of 71,092 patients with type 2
diabetes aged  60 years evaluated the relationships
between baseline A1C and subsequent outcomes (acute
nonfatal metabolic, microvascular, and cardiovascular
events and mortality). As in the prior study, mortality
had a U-shaped relationship with A1C. Compared to
risk with A1C <6.0%, mortality risk was lower for
A1C between 6.0 and 9.0% and higher at A1C
11.0%. Risk of any end point (complication or death)
became significantly higher at A1C 8.0%. Patterns
were generally consistent across age-groups (60–69, 70–
79, and  80 years).35
Diabetes is associated with increased risk of multiple
coexisting medical conditions in older adults ranging from
CVD to cancer and potentially impacting treatment deci-
sions, such as whether stringent glycemic control would be
of net benefit.36,37 A 5-year longitudinal, observational
study of Italian patients with type 2 diabetes categorized
patients into subgroups of high (mean age 64.3 years [SD
9.5]) and low-to-moderate comorbidity (mean age
61.7 years [SD 10.5]) using a validated patient-reported
measure of comorbidity. Having an A1C of  6.5
or <7% at baseline was associated with lower 5-year inci-
dence of cardiovascular events in the low-to-moderate
comorbidity subgroup, but not in the high comorbidity
subgroup, suggesting that patients with high levels of
comorbidity may not receive cardiovascular benefit from
intensive blood glucose control.38
Lipid Lowering
There are no large trials of lipid-lowering interventions
specifically in older adults with diabetes. Benefits have
been extrapolated from trials of older adults that include
but are not limited to those with diabetes and trials of
people with diabetes including but not limited to older
adults. A statin study in older adults (participants aged
70–82 years) found a 15% reduction in coronary artery
disease events with pravastatin.39,40 A meta-analysis of
18,686 people with diabetes in 14 trials of statin therapy
for primary prevention showed similar 20% relative reduc-
tions in major adverse vascular outcomes in those under
compared with those aged 65 years.41 Statin trials for
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secondary prevention of CVD in adults with diabetes have
also demonstrated comparable relative reductions in recur-
rent cardiovascular events and mortality by age-group.42
Since older patients are at higher risk, absolute risk reduc-
tions with statin therapy would be greater in older
patients. Cardiovascular prevention with statins, especially
secondary benefit, emerges fairly quickly (within 1–2
years), suggesting that statins may be indicated in nearly
all older adults with diabetes except those with very
limited life expectancy.
The evidence for reduction in major cardiovascular
end points with drugs other than statins is limited in any
age-group. The ACCORD lipid trial found no benefit of
adding fenofibrate to statin therapy,43 and post hoc analy-
ses suggested that the negative results applied to both
those under and those aged  65 years (M. Miller, per-
sonal communication). Subgroup analyses of the Fenofi-
brate Intervention and Event Lowering in Diabetes
(FIELD) study, which suggested some benefit of fenofibrate
in people with type 2 diabetes, suggested no benefit in
those aged 65 years of age.44
Blood Pressure Control
Multiple trials have investigated the role of treatment of
hypertension to reduce the risk of cardiovascular events.17
Benefit for older adults with diabetes has been inferred from
the trials of older adults including but not limited to those
with diabetes and from the trials of middle- and older-aged
adults with diabetes.42 There is consistent evidence that low-
ering blood pressure from very high levels (e.g., systolic
blood pressure [SBP] 170 mmHg) to moderate targets (e.g.,
SBP 150 mmHg) reduces cardiovascular risk in older adults
with diabetes. Selected trials have shown benefit with targets
progressively lower, down to SBP < 140 mmHg and dia-
stolic blood pressure (DBP) <80 mmHg.45 The ACCORD-
BP trial showed no benefit on the primary outcome (major
adverse cardiovascular events) of SBP targets <120 mmHg
compared with <140 mmHg, but found a significant reduc-
tion in stroke, a secondary outcome.46 Subgroup analyses of
those aged < versus  65 years suggested that the stroke ben-
efit may have been limited to the older cohort (M. Miller, per-
sonal communication).
Observational analyses of other trial cohorts suggest no
benefit to SBP targets more aggressive than <140 mmHg
and that low DBP may be a risk factor for mortality in
older adults. A post hoc analysis of the cohort of partici-
pants with diabetes in the International Verapamil SR-
Trandolapril Study (INVEST), whose mean age was
~65 years, showed that achieved SBP under 130 mmHg
was not associated with improved cardiovascular outcomes
compared with SBP under 140 mmHg.47 This report
validated SBP control under 140 mmHg, as death and
cardiovascular events were more likely in subjects whose
SBP was over 140 mmHg. A post hoc analysis of the VADT
(in which the goal blood pressure was <130/80 mmHg)
similarly showed that those whose SBP was  140 mmHg
had increased mortality, while those at <105 mmHg,
105–129 mmHg, and 130–139 mmHg had equally low
mortality rates. For DBP, achieved values <70 mmHg were
associated with higher mortality, while those of 70–
79 mmHg or >80 mmHg were equally low.48
Aspirin
In populations without diabetes, the greatest absolute benefit
of aspirin therapy (75–162 mg) is for individuals with a 10-
year risk of coronary heart disease of 10% or greater.49 The
increased cardiovascular risk posed by diabetes and aging
and the known benefits of aspirin for secondary prevention
suggest that, in the absence of contraindications, this therapy
should be offered to virtually all older adults with diabetes
and known CVD. However, the benefits of aspirin for pri-
mary prevention of CVD events have not been thoroughly
elucidated in older adults with diabetes and must be bal-
anced against risk of adverse events such as bleeding. A ran-
domized study of Japanese individuals with diabetes but no
CVD history demonstrated no significant benefit of aspirin
on the composite primary outcome, but a subgroup analysis
of subjects aged  65 years demonstrated a significantly
lower risk of the primary end point with aspirin.50
The incidence of gastrointestinal bleeding with the use
of aspirin has not been directly compared in older- versus
middle-aged adults, but in separate studies the rates were
higher (1–10 per 1,000 annually) for older adults51 than
those for middle-aged adults (3 per 10,000 annually).49More
recently, the greater risk of major gastrointestinal or intrace-
rebral bleeding in older adults who use aspirin was suggested
by an observational analysis, but diabetes per se was not
associated with increased bleeding with aspirin.52 In light of
the probable higher risk of bleeding with age, the benefit of
aspirin therapy in older adults with diabetes is likely strong-
est for those with high cardiovascular risk and low risk of
bleeding. Unfortunately, the risk factors for these outcomes
tend to overlap. When aspirin is initiated, the use of agents
such as proton pump inhibitors to protect against gastroin-
testinal bleeding may be warranted.53 Further evidence is
needed to confirm a clear role of aspirin for primary preven-
tion of cardiovascular events in older adults with diabetes.
Screening for Chronic Diabetes Complications
The screening and interventions for chronic diabetes com-
plications recommended by the ADA have a strong evi-
dence base and are cost-effective.54 However, as is the case
for many diabetes interventions, the underlying evidence
generally comes from studies of younger adults. When con-
sidering chronic complications, the issues of incident versus
prevalent diabetes and diabetes heterogeneity again need to
be raised. Some older adults have long-standing diabetes
with associated microvascular and macrovascular compli-
cations. Others have newly diagnosed diabetes with evi-
dence of complications (on screening tests) at initial
presentation, while still others have newly diagnosed diabe-
tes without evidence of complications. For relatively
healthy older adults with long life expectancy, following
the screening recommendations for all adults with diabetes
is reasonable. For very old patients and/or those with mul-
tiple comorbidities and short life expectancy, it is prudent
to weigh the expected benefit time frame of identifying
early signs of complications and intervening to prevent
worsening to end-stage disease. For the latter group, partic-
ular attention should be paid to screening for risk factors
of complications that might further impair functional status
or quality of life over a relatively short period of time, such
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as foot ulcers/amputations and visual impairment. Consid-
erations in clinical decision-making should also include
prior test results. For example, there is evidence, including
in the older adult population, that dilated eye examinations
that are initially normal can safely be repeated every 2–
3 years instead of yearly.55
WHAT CURRENT GUIDELINES EXIST FOR
TREATING DIABETES IN OLDER ADULTS?
Several organizations have developed diabetes guidelines
specific to, or including, older adults. The ADA includes a
section on older adults in its annual Standards of Medical
Care in Diabetes.17 The section discusses the heterogeneity
of persons aged 65 years and the lack of high-level evi-
dence. The overall recommendations, all based on expert
opinion, include the following:
● Older adults who are functional, are cognitively intact,
and have significant life expectancy should receive dia-
betes care using goals developed for younger adults.
● Glycemic goals for older adults not meeting the above
criteria may be relaxed using individualized criteria, but
hyperglycemia leading to symptoms or risk of acute hyper-
glycemic complications should be avoided in all patients.
● Other cardiovascular risk factors should be treated in
older adults with consideration of the timeframe of
benefit and the individual patient. Treatment of hyper-
tension is indicated in virtually all older adults, and
lipid and aspirin therapy may benefit those with life
expectancy at least equal to the timeframe of primary
or secondary prevention trials.
● Screening for diabetes complications should be individ-
ualized in older adults, but particular attention should
be paid to complications that would lead to functional
impairment.
The ADA goals for glycemic control do not specifi-
cally mention age. The recommendation for many adults is
an A1C <7%, but less stringent goals are recommended
for those with limited life expectancy, advanced diabetes
complications, or extensive comorbid conditions.17
In collaboration with the ADA and other medical
organizations, the California HealthCare Foundation/
American Geriatrics Society panel published guidelines for
improving the care of older adults with diabetes in 2003.
A significant proportion of the recommendations concerns
geriatric syndromes. Highlights of diabetes-specific recom-
mendations include A1C targets of 7.0% in “relatively
healthy adults,” while for those who are frail or with life
expectancy less than 5 years, a less stringent target, such
as 8%, was considered appropriate. The guidelines also
suggested that the timeline of benefits was estimated to be
at least 8 years for glycemic control and 2–3 years for
blood pressure and lipid control.2
The U.S. Department of Veterans Affairs and the U.S.
Department of Defense (VA/DOD) diabetes guidelines
were updated in 2010. As with other guidelines, the VA/
DOD guidelines do not distinguish by age-group. They
highlight the frequency of comorbid conditions in patients
with diabetes and stratify glycemic goals based on comor-
bidity and life expectancy. For glycemic goals, for exam-
ple, the guidelines have three categories:
● The patient with either none or very mild microvascu-
lar complications of diabetes, who is free of major
concurrent illnesses and who has a life expectancy of at
least 10–15 years, should have an A1C target of <7%,
if it can be achieved without risk.
● The patient with longer duration diabetes (more than
10 years) or with comorbid conditions and who
requires a combination medication regimen including
insulin should have an A1C target of <8%.
● The patient with advanced microvascular complications
and/or major comorbid illness and/or a life expectancy
of less than 5 years is unlikely to benefit from aggres-
sive glucose-lowering management and should have an
A1C target of 8–9%. Lower targets (<8%) can be
established on an individual basis.56
The European Diabetes Working Party for Older Peo-
ple recently published guidelines for treating people with
diabetes aged 70 years. These extensive guidelines rec-
ommend that “the decision to offer treatment should be
based on the likely benefit/risk ratio of the intervention for
the individual concerned, but factors such as vulnerability
to hypoglycemia, ability to self-manage, the presence or
absence of other pathologies, the cognitive status, and life
expectancy must be considered.”57 There are recommenda-
tions to carry out annual evaluations of functional status
(global/physical, cognitive, affective) using validated instru-
ments to avoid the use of glyburide due to its high risk of
hypoglycemia in this population and to calculate cardiovas-
cular risk in all patients less than 85 years of age. Suggested
A1C targets are based on age and comorbidity. A range of 7
–7.5% is suggested for older patients with type 2 diabetes
without major comorbidities and 7.6–8.5% for frail patients
(dependent, multisystem disease, home care residency
including those with dementia) where the hypoglycemia risk
may be high and the likelihood of benefit relatively low.
Extensive review of the guidelines is beyond the scope
of this report, but there are similar themes, which suggest
pursuing an individualized approach with a focus on clini-
cal and functional heterogeneity and comorbidities, and
weighing the expected time frame of benefit of interven-
tions against life expectancy.
WHAT ISSUES NEED TO BE CONSIDERED IN
INDIVIDUALIZING TREATMENT
RECOMMENDATIONS FOR OLDER ADULTS?
Comorbidities and Geriatric Syndromes
Diabetes is associated with increased risk of multiple coex-
isting medical conditions in older adults. In addition to the
classic cardiovascular and microvascular diseases, a group
of conditions termed geriatric syndromes, described below,
also occur at higher frequency in older adults with diabe-
tes and may affect self-care abilities and health outcomes
including quality of life.58
Cognitive Dysfunction
Alzheimer’s-type and multi-infarct dementia are approxi-
mately twice as likely to occur in those with diabetes com-
pared with age-matched nondiabetic control subjects.59 The
presentation of cognitive dysfunction can vary from subtle
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executive dysfunction to overt dementia and memory loss. In
the ACCORD trial, for which referred participants were felt
to be capable of adhering to a very complex protocol, 20%
of those in the ancillary trial of cognition were found to
have undiagnosed cognitive dysfunction at baseline (J. Wil-
liamson, personal communication).60 In this trial, neither
intensive glycemic control nor blood pressure control to a
target SBP <120 mmHg was shown to prevent a decline in
brain function.61 Cross-sectional studies have shown an
association between hyperglycemia and cognitive dysfunc-
tion.62 Hypoglycemia is linked to cognitive dysfunction in a
bidirectional fashion: cognitive impairment increases the
subsequent risk of hypoglycemia,60 and a history of severe
hypoglycemia is linked to the incidence of dementia.63
High rates of unidentified cognitive deficits in older
adults suggest that it is important to periodically screen
for cognitive dysfunction. Simple assessment tools can be
accessed at www.hospitalmedicine.org/geriresource/tool-
box/howto.htm. Such dysfunction makes it difficult for
patients to perform complex self-care tasks such as glucose
monitoring, changing insulin doses, or appropriately main-
taining timing and content of diet. In older patients with
cognitive dysfunction, regimens should be simplified, care-
givers involved, and the occurrence of hypoglycemia care-
fully assessed.
Functional Impairment
Aging and diabetes are both risk factors for functional
impairment. After controlling for age, people with diabetes
are less physically active and have more functional impair-
ment than those without diabetes.64,65 The etiology of
functional impairment in diabetes may include interaction
between coexisting medical conditions, peripheral neuropa-
thy, vision and hearing difficulty, and gait and balance
problems. Peripheral neuropathy, present in 50–70% of
older patients with diabetes, increases the risk of postural
instability, balance problems, and muscle atrophy,66–68 lim-
iting physical activity and increasing the risk of falls. Other
medical conditions that commonly accompany diabetes
such as coronary artery disease, obesity, degenerative joint
disease, stroke, depression, and visual impairment also neg-
atively impact physical activity and functionality.69
Falls and Fractures
Normal aging and diabetes, and the conditions described
above that impair functionality, are associated with the
higher risk of falls and fractures.70,71 Women with diabetes
have a higher risk of hip and proximal humeral fractures
after adjustment for age, body mass index (BMI), and bone
density.71 It is important to assess fall risks and perform
functional assessment periodically in older adults.72 Avoid-
ance of severe hyperglycemia and hypoglycemia can
decrease the risk of falls. Physical therapy should be encour-
aged in patients who are at high risk or who have experi-
enced a recent fall. Medicare may cover physical therapy for
a limited time in some of these situations.
Polypharmacy
Older adults with diabetes are at high risk of polypharma-
cy, increasing the risk of drug side effects and drug-to-drug
interactions. A challenge in treating type 2 diabetes is that
polypharmacy may be intentional and necessary to control
related comorbidities and reduce the risk of diabetes com-
plications.73,74 In one study, polypharmacy (defined as the
use of 6 or more prescription medications) was associated
with an increased risk of falling in older people.75 The
costs of multiple medications can be substantial, especially
when older patients fall into the “doughnut hole” of Medi-
care Part D coverage. Medication reconciliation, ongoing
assessment of the indications for each medication, and the
assessment of medication adherence and barriers are
needed at each visit.
Depression
Diabetes is associated with a high prevalence of depres-
sion.76 Untreated depression can lead to difficulty with self-
care and with implementing healthier lifestyle choices77 and
is associated with a higher risk of mortality and dementia in
patients with diabetes.78,79 In older adults, depression may
remain undiagnosed if screening is not performed. Clinical
tools such as the Geriatric Depression Scale80 can be used to
periodically screen older patients with diabetes.
Vision and Hearing Impairment
Sensory impairments should be considered when educating
older adults and supporting their self-care. Nearly one in
five older U.S. adults with diabetes report visual impair-
ment.81 Hearing impairment involving both high- and low-
mid-frequency sound is about twice as prevalent in people
with diabetes, even after controlling for age82 and may be
linked to both vascular disease and neuropathy.83
Other Commonly Occurring Medical Conditions
Persistent pain from neuropathy or other causes or its inad-
equate treatment is associated with adverse outcomes in
older adults including functional impairment, falls, slow
rehabilitation, depression and anxiety, decreased socializa-
tion, sleep and appetite disturbances, and higher healthcare
costs and utilization.2 Pain should be assessed at every visit
in older patients with the implementation of strategies for
amelioration of pain. Urinary incontinence is common in
older patients, especially women, with diabetes. In addition
to standard assessments and treatments for incontinence,
clinicians should remember that uncontrolled hyperglyce-
mia can increase the amount and frequency of urination.
Unique Nutrition Issues
Nutrition is an integral part of diabetes care for all ages,
but there are additional considerations for older adults
with diabetes. Though energy needs decline with age, mac-
ronutrient needs are similar throughout adulthood. Meet-
ing micronutrient needs with lower caloric intake is
challenging; therefore older adults with diabetes are at
higher risk for deficiencies. Older adults may be at risk for
undernutrition due to anorexia, altered taste and smell,
swallowing difficulties, oral/dental issues, and functional
impairments leading to difficulties in preparing or consum-
ing food. Overly restrictive eating patterns, either self-
imposed or provider-directed, may contribute additional
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risk for older adults with diabetes. The Mini-Nutritional
Assessment, specifically designed for older adults, is simple
to perform and may help determine whether referral to a
registered dietitian for medical nutrition therapy (MNT) is
needed (http://www.mna-elderly.com/).
MNT has proven to be beneficial in older adults with
diabetes.84 Recommendations should take into account the
patient’s culture, preferences, and personal goals and abili-
ties. When nutrition needs are not being met with usual
intake, additional interventions may include encouraging
smaller more frequent meals, fortifying usual foods, chang-
ing food texture, or adding liquid nutrition supplements
(either regular or diabetes-specific formulas) between
meals. For nutritionally vulnerable older adults, identifying
community resources such as Meals on Wheels, senior cen-
ters, and the U.S. Department of Agriculture’s Older
Americans Nutrition Program may help maintain indepen-
dent living status.
Overweight and obesity are prevalent among older
adults. BMI may not be an accurate predictor of the
degree of adiposity in some older adults due to changes in
body composition with aging.85 Sarcopenia may occur in
both over- and underweight older adults. Obesity exacer-
bates decline in physical function due to aging and
increases the risk of frailty.86 While unintentional weight
loss is a known nutrition concern, intentional weight loss
in overweight and obese older adults could potentially
worsen sarcopenia, bone mineral density, and nutrition
deficits.87,88 Strategies that combine physical activity with
nutrition therapy to promote weight loss may result in
improved physical performance and function and reduced
cardiometabolic risk in older adults.86,87
Unique Needs in Diabetes Self-Management Education/
Training and Support
As with all persons with diabetes, diabetes self-management
education/training (DSME/T) for older adults should be
individualized to the patient’s unique medical, cultural, and
social situation. Additionally, for older adults, DSME/T
may need to account for possible impairments in sensation
(vision, hearing), cognition, and functional/physical status.
Care partners—family, friends, or other caregivers—should
be involved in DSME/T to increase the likelihood of success-
ful self-care behaviors.89 When communicating with cogni-
tively impaired patients, educators should address the
patient by name (even when a caregiver will provide most
care), speak in simple terms, use signals (cues) that aid mem-
ory (verbal analogies, hands-on experience, demonstrations
and models), and utilize strategies such as sequenced visits
to build on information. Other tactics include summarizing
important points frequently, focusing on one skill at a time,
teaching tasks from simple to complex, and providing easy-
to-read handouts. Even in the absence of cognitive impair-
ment, educators should consider that many patients may
have low health literacy and numeracy skills or may be
overwhelmed by the presence of multiple comorbidities.
Physical Activity and Fitness
Muscle mass and strength decline with age, and these
decrements may be exacerbated by diabetes complications,
comorbidities, and periods of hospitalization in older
adults with diabetes. People with diabetes of longer dura-
tion and those with higher A1C have lower muscle
strength per unit of muscle mass than BMI- and age-
matched people without diabetes and than those whose
disease is of shorter duration or under better glycemic con-
trol.90 Although age and diabetes conspire to reduce fitness
and strength, physical activity interventions improve func-
tional status in older adults91 with and without diabetes.
In the Look AHEAD (Action for Health in Diabetes)
study, participants aged 65–76 years had lower gains in
fitness with the intensive lifestyle intervention than youn-
ger patients, but still improved their measures of fitness by
a mean of over 15%.92 In older adults, even light-intensity
physical activity is associated with higher self-rated physi-
cal health and psychosocial well-being.93
Older adults with diabetes who are otherwise healthy
and functional should be encouraged to exercise to targets
recommended for all adults with diabetes.17 Even patients
with poorer health status benefit from modest increases in
physical activity. Tactics to facilitate activity for older
adults may include referring to supervised group exercise
and community resources such as senior centers, YMCAs,
the EnhanceFitness program, and the resources of the
Arthritis Foundation.
Age-Specific Aspects of Pharmacotherapy
Older patients are at increased risk for adverse drug events
from most medications due to age-related changes in phar-
macokinetics (in particular reduced renal elimination) and
pharmacodynamics (increased sensitivity to certain medica-
tions) affecting drug disposition. These changes may trans-
late into increased risk for hypoglycemia, the potential
need for reduced doses of certain medications, and atten-
tion to renal function to minimize side effects.94,95 The
risk for medication-related problems is compounded by
the use of complex regimens, high-cost therapies, and
polypharmacy or medication burden. Collectively, these
factors should be considered and weighed against the
expected benefits of a therapy before incorporating it into
any therapeutic plan. Attention to the selection of medica-
tions with a strong benefit-to-risk ratio is essential to
promote efficacy, persistence on therapy, and safety.
Antihyperglycemic Medication Use in Older Adults
Comparative effectiveness studies of medications to treat
diabetes in older adult populations are lacking. Type 2
diabetes with onset later in life is characterized by promi-
nent defects in b-cell function, suggesting therapeutic
attention to b-cell function and sufficiency of insulin
release, as well as the traditional focus on hepatic glucose
overproduction and insulin resistance. Understanding the
advantages and disadvantages of each antihyperglycemic
drug class helps clinicians individualize therapy for
patients with type 2 diabetes.96 Issues particularly relevant
to older patients are described for each drug class.
Metformin is often considered the first-line therapy in
type 2 diabetes. Its low risk for hypoglycemia may be ben-
eficial in older adults, but gastrointestinal intolerance and
weight loss from the drug may be detrimental in frail
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patients. Despite early concerns, the evidence for an
increase in the risk of lactic acidosis with metformin is
minimal. The dose should be reduced if estimated glomer-
ular filtration rate (eGFR) is 30–60 mL/min, and the drug
should not be used if eGFR is <30 mL/min.94,97 Metfor-
min’s low cost may be a benefit in those on multiple medi-
cations or who are subject to the Medicare Part D
“doughnut hole.”
Sulfonylureas are also a low-cost class of medications,
but the risk of hypoglycemia with these agents may be
problematic for older patients. Glyburide has the highest
hypoglycemia risk and should not be prescribed for older
adults.98 Glinides are dosed prior to meals, and their short
half-life may be useful for postprandial hyperglycemia.
They impart a lower risk for hypoglycemia than sulfonylu-
reas, especially in patients who eat irregularly, but their
dosing frequency and high cost may be barriers.
a-Glucosidase inhibitors specifically target postpran-
dial hyperglycemia and have low hypoglycemia risk, mak-
ing them theoretically attractive for older patients.
However, gastrointestinal intolerance may be limiting, fre-
quent dosing adds to regimen complexity, and this class of
medications is costly. Thiazolidinediones have associated
risks of weight gain, edema, heart failure, bone fractures,
and possibly bladder cancer, which may argue against
their use in older adults. The use of rosiglitazone is now
highly restricted. The class has traditionally been expen-
sive, although the approval of generic pioglitazone may
reduce its cost.
Dipeptidyl peptidase-4 inhibitors are useful for post-
prandial hyperglycemia, impart little risk for hypoglyce-
mia, and are well tolerated, suggesting potential benefits
for older patients. However, their high cost may be limit-
ing. Glucagon-like peptide-1 agonists also target postpran-
dial hyperglycemia and impart low risk of hypoglycemia,
but their associated nausea and weight loss may be prob-
lematic in frail older patients. Injection therapy may add
to regimen complexity, and its very high cost may be prob-
lematic. For some agents, dose reduction is required for
renal dysfunction.
Insulin therapy can be used to achieve glycemic goals
in selected older adults with type 2 diabetes with similar
efficacy and hypoglycemia risk as in younger patients.
However, given the heterogeneity of the older adult popu-
lation, the risk of hypoglycemia must be carefully consid-
ered before using an insulin regimen to achieve an
aggressive target for hyperglycemia control. A mean A1C
of 7% was achieved and maintained for 12 months with
either an insulin pump regimen or multiple daily insulin
injections in otherwise healthy and functional older adults
(mean age 66 years), with low rates of hypoglycemia.99
The addition of long-acting insulin was similarly effective
in achieving A1C goals for older patients with type 2 dia-
betes (mean age 69 years) in a series of trials with no
greater rates of hypoglycemia than in younger patients
(mean age 53 years).100 However, there are few data on
such regimens in people aged >75 years or in older adults
with multiple comorbidities and/or limited functional sta-
tus who were excluded from these trials.
Problems with vision or manual dexterity may be bar-
riers to insulin therapy for some older adults. Pen devices
improve ease of use but are more costly than the use of
vials and syringes. Hypoglycemia risk (especially noctur-
nal) is somewhat lower with analog compared with human
insulins, but the former are more expensive. Insulin-
induced weight gain is a concern for some patients, and
the need for more blood glucose monitoring may increase
treatment burden.
Other approved therapies for which there is little evi-
dence in older patients include colesevelam, bromocriptine,
and pramlintide. An emerging drug class, sodium-glucose
cotransporter-2 inhibitors, may require additional study in
older adults to assess whether drug-associated genital
infections or urinary incontinence is problematic in this
population.
Vulnerability to Hypoglycemia
Age appears to affect counter-regulatory responses to hypo-
glycemia in nondiabetic individuals. During hypoglycemic
clamp studies, symptoms begin at higher glucose levels and
have greater intensity in younger men (aged 22–26 years),
while measures of psychomotor coordination deteriorate
earlier and to a greater degree in the older subjects (aged
60–70 years), erasing the usual 10–20 mg/dL plasma glu-
cose difference between subjective awareness of hypoglyce-
mia and onset of cognitive dysfunction.101 Studies in older
individuals with diabetes are limited. One small study com-
pared responses to hypoglycemic clamps in older (mean age
70 years) versus middle-aged (mean age 51 years) people
with type 2 diabetes. Hormonal counter-regulatory
responses to hypoglycemia did not differ between age-
groups, but middle-aged participants had a significant
increase in autonomic and neuroglycopenic symptoms at
the end of the hypoglycemic period, while older partici-
pants did not. Half of the middle-aged participants, but
only 1 out of 13 older participants, correctly reported that
their blood glucose was low during hypoglycemia.102
The prevalence of any hypoglycemia (measured blood
glucose below 70 mg/dL) or severe hypoglycemia (requiring
third-party assistance) in older populations is not known.
In the ACCORD trial, older participants in both glycemic
intervention arms had ~50% higher rates of severe
hypoglycemia (hypoglycemia requiring third-party assis-
tance) than participants under age 65 years (M. Miller,
personal communication). In a population analysis of
Medicaid enrollees treated with insulin or sulfonylureas,
the incidence of serious hypoglycemia (defined as that lead-
ing to emergency department visit, hospitalization, or
death) was approximately 2 per 100 person-years,103 but
clearly studies based on administrative databases miss less
catastrophic hypoglycemia.
The risk factors for hypoglycemia in diabetes in gen-
eral (use of insulin or insulin secretagogues, duration of
diabetes, antecedent hypoglycemia, erratic meals, exercise,
renal insufficiency)104 presumably apply to older patients
as well. In the Medicaid study cited above, independent
risk factors included hospital discharge within the prior
30 days, advanced age, black race, and use of five or more
concomitant medications.103 Assessment of risk factors for
hypoglycemia is an important part of the clinical care of
older adults with hypoglycemia. Education of both patient
and caregiver on the prevention, detection, and treatment
of hypoglycemia is paramount.
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Risks of Undertreatment of Hyperglycemia
Although attention has rightly been paid to the risks of
overtreatment of hyperglycemia in older adults (hypoglyce-
mia, treatment burden, possibly increased mortality),
untreated or undertreated hyperglycemia also has risks,
even in patients with life expectancy too short to be
impacted by the development of chronic complications.
Blood glucose levels consistently over the renal threshold
for glycosuria (~180–200 mg/dL, but can vary) increase
the risks for dehydration, electrolyte abnormalities, urinary
incontinence, dizziness, and falls. Hyperglycemic hyper-
osmolar syndrome is a particularly severe complication of
unrecognized or undertreated hyperglycemia in older
adults. Although it is appropriate to relax glycemic targets
for older patients with a history of hypoglycemia, a high
burden of comorbidities, and limited life expectancy, goals
that minimize severe hyperglycemia are indicated for
almost all patients.
Life Expectancy
A central concept in geriatric diabetes care guidelines is
that providers should base decisions regarding treatment
targets or interventions on life expectancy.2,17,57 Patients
whose life expectancy is limited (e.g., <5 years, <10 years)
are considered unlikely to benefit from intensive glucose
control, for example, whereas those with longer life expec-
tancy may be appropriate candidates for this intervention.
An observation supporting this concept is that cumulative
event curves for the intensive and conventional glycemic
control arms of the UKPDS separated after the 9-year
mark.
National Vital Statistics life table estimates of average
life expectancy for adults of specific ages, sexes, and
races105 may not apply to older adults with diabetes, who
have shorter life expectancies than the average older adult.
Mortality prediction models that account for variables
such as comorbidities and functional status can serve as
the basis for making more refined life expectancy esti-
mates.106–108 Mortality prediction models specific to diabe-
tes exist but were not designed to inform treatment
decisions.109,110 A limitation of existing mortality models
is that they can help to rank patients by probability of
death, but these probabilities must still be transformed into
a life expectancy for a particular older diabetic patient.
Simulation models can help transform mortality pre-
diction into a usable life expectancy. One such model esti-
mated the benefits of lowering A1C from 8.0 to 7.0% for
hypothetical older diabetic patients with varying levels of
age, comorbidity, and functional status.111 A combination
of multiple comorbid illnesses and functional impairments
was a better predictor of limited life expectancy and
diminished benefits of intensive glucose control than age
alone. This model suggests that life expectancy averages
less than 5 years for patients aged 60–64 years with seven
additional index points (points due to comorbid conditions
and functional impairments), aged 65–69 years with six
additional points, aged 70–74 years with five additional
points, and aged 75–79 years with four additional points.
An example of comorbid illnesses is the diagnosis of can-
cer, which confers two points, whereas an example of a
functional impairment is the inability to bathe oneself,
conferring two points.
Shared Decision-Making
In light of the paucity of data for diabetes care in older
adults, treatment decisions are frequently made with con-
siderable uncertainty. Shared decision-making has been
advocated as an approach to improving the quality of
these so-called preference-sensitive medical decisions.112,113
Key components of the shared decision-making approach
are (1) establishing an ongoing partnership between
patient and provider, (2) information exchange, (3) delib-
eration on choices, and (4) deciding and acting on deci-
sions.114
When asked about their healthcare goals, older dia-
betic patients focus most on their functional status and
independence.115 A key component of improving commu-
nication in the clinical setting may be finding congruence
between patient goals and the biomedical goals on which
clinicians tend to focus. Discussions eliciting and incorpo-
rating patients’ preferences regarding treatments and treat-
ment targets may be difficult when patients do not
understand the significance of risk factors or the value of
risk reduction. Thus, providers must first educate patients
and their caregivers about what is known about the role
of risk factors in the development of complications and
then discuss the possible harms and benefits of interven-
tions to reduce these risk factors.
Equally important is discussing the actual medications
that may be needed to achieve treatment goals because
patients may have strong preferences about the treatment
regimen. In a study of patient preferences regarding diabe-
tes complications and treatments, end-stage complications
had the greatest perceived burden on quality of life; how-
ever, comprehensive diabetes treatments had significant
negative perceived quality-of-life effects, similar to those of
intermediate complications.116 Preferences for each health
state varied widely among patients, and this variation was
not related to health status,117 implying that the prefer-
ences of an individual patient cannot be assumed to be
known based on health status.
Many older adults rely on family members or friends
to help them with their treatment decisions or to imple-
ment day-to-day treatments. In the case of the older person
with cognitive deficits, the family member or friend may in
fact be serving as a surrogate decision-maker. Prior studies
of older cognitively intact patients have shown that surro-
gate decision-makers often report treatment preferences for
the patient that have little correlation with the patient’s
views,118 highlighting the importance of eliciting patient
preferences whenever possible.
Racial and Ethnic Disparities
Among older adults, African Americans and Hispanics
have higher incidence and prevalence of type 2 diabetes
than non-Hispanic whites, and those with diagnosed
diabetes have worse glycemic control and higher rates of
comorbid conditions and complications.119 The Institute of
Medicine found that although healthcare access and demo-
graphic variables account for some racial and ethnic dis-
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parities, there are persistent, residual gaps in outcomes
attributed to differences in the quality of care received.120
There is clearly a need for more research into the dispari-
ties in diabetes, particularly to understand the full impact
of quality improvement programs and culturally tailored
interventions among vulnerable older adults with diabetes.
Settings Outside the Home
Long-Term Care Facilities
Long-term care (LTC) facilities include nursing homes,
which provide 24-hour nursing care for patients in either
residential care or rehabilitative care, and adult family
homes where the level of care is not as acute. Diabetes is
common in LTC facilities, with an overall diabetes preva-
lence of 25% (22% in Caucasian and 36% in non-Cauca-
sian residents).121 LTC residents with diabetes have more
falls,122 higher rates of CVD and depression, more func-
tional impairment, and more cognitive decline and depen-
dency than residents without diabetes.123
The LTC facility resident may have irregular and unpre-
dictable meal consumption, undernutrition, anorexia, and
impaired swallowing. Therapeutic diets may inadvertently
lead to decreased food intake and contribute to uninten-
tional weight loss and undernutrition. Serving meals that
take into account the patient’s culture, preferences, personal
goals, and abilities may increase quality of life, satisfaction
with meals, and nutrition status.124 Vulnerable older adults,
particularly those with cognitive dysfunction, may have
impaired thirst sensation, contributing to the risk of volume
depletion and hyperglycemic crises. Precipitating situations
include illness, institutional settings (LTC or hospital), aver-
sion to drinking water, dysphasia requiring thickened liq-
uids, and some medications.125 Fluid intake should be
encouraged and monitored in an institutional setting.
A major issue in LTC facilities is frequent staff turnover
with resultant unfamiliarity with vulnerable residents.126
There is often inadequate oversight of glycemic control
related to infrequent review of glycemic trends, complex
and difficult-to-read glucose logs, and lack of specific diabe-
tes treatment algorithms including glycemic parameters for
provider notification.127 Excessive reliance on sliding-scale
insulin (SSI) has been documented. One study showed that
83% of residents started on SSI were still treated by SSI
alone 6 months later.128 Evidence-based policies for glyce-
mic control, use of insulin, and treatment of hypoglycemia
have the potential to improve the care of residents with dia-
betes, alleviate some of the burden caused by frequent staff
turnover, and even lead to more staff satisfaction.
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This represents a consensus framework for considering treatment goals for glycemia, blood pressure, and dyslipidemia in older adults with diabetes. The
patient characteristic categories are general concepts. Not every patient will clearly fall into a particular category. Consideration of patient/caregiver prefer-
ences is an important aspect of treatment individualization. Additionally, a patient’s health status and preferences may change over time. ADL = activities
of daily living.
a Coexisting chronic illnesses are conditions serious enough to require medications or lifestyle management and may include arthritis, cancer, congestive
heart failure, depression, emphysema, falls, hypertension, incontinence, stage III or worse chronic kidney disease, MI, and stroke. By multiple we mean at
least three, but many patients may have five or more.132
b The presence of a single end-stage chronic illness such as stage III–IV congestive heart failure or oxygen-dependent lung disease, chronic kidney disease
requiring dialysis, or uncontrolled metastatic cancer may cause significant symptoms or impairment of functional status and significantly reduce life
expectancy.
c A1C of 8.5% equates to an estimated average glucose of ~200 mg/dL. Looser glycemic targets than this may expose patients to acute risks from
glycosuria, dehydration, hyperglycemic hyperosmolar syndrome, and poor wound healing.
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Hospitals
Older adults are more apt to require hospitalization than
younger adults, and those with diabetes are at very high
risk of requiring hospitalization. There is a dearth of stud-
ies addressing older adults with diabetes, particularly more
frail older adults, in the hospital. Many guidelines that
apply to hospitalized adults with hyperglycemia can proba-
bly be extrapolated to older adults.129,130 Current
guidelines recommend preprandial glycemic targets of 100
–140 mg/dL with maximal random values of 180 mg/dL
in the majority of noncritically ill hospitalized patients,
provided these targets can be safely achieved with low risk
for hypoglycemia. Less stringent glycemic targets may be
appropriate for patients with multiple comorbidities and
reduced life expectancy—criteria that could be applicable
to many hospitalized older adults. However, in general,
glucose levels should be maintained at values below
200 mg/dL to minimize symptomatic hyperglycemia with
associated fluid and electrolyte abnormalities, renal com-
plications, and risk for infection.129,130 Studies of glycemic
control targets in critically ill patients did include older
adults, and therefore the recommendations for insulin infu-
sions and glycemic goals of the ADA17 are reasonable for
older adults in intensive care units. Other recommenda-
tions for all adults, such as avoiding the use of sliding
scale–only regimens and noninsulin antihyperglycemic
drugs, are also reasonable for hospitalized older adults.
Transitions from hospital to home or to short- or
long-term care facilities are times of risk for patients with
diabetes, and probably more so for older patients. Older
patients on insulin may need to increase or decrease their
dose as they recuperate from their acute illness and their
diet improves. Delirium (acute decline in cognitive func-
tion) is a common complication seen in older adults during
and after hospitalization and may require more supervision
to avoid errors in dosing. Medication reconciliation,
patient and caregiver education, and close communication
between inpatient and outpatient care teams, are critically
important to ensure patient safety and reduce readmission
rates.
WHAT ARE CONSENSUS RECOMMENDATIONS
FOR CLINICIANS TREATING OLDER ADULTS
WITH OR AT RISK FOR DIABETES?
Although several organizations have developed guidelines
that pertain to older adults and/or those with significant
comorbidity, lack of evidence makes it somewhat difficult
to provide concrete guidance for clinicians. After review of
the available evidence and consideration of issues that
might influence treatment decisions in older adults with
diabetes, the authors have developed recommendations in
a number of areas. Table 1 provides a framework for con-
sidering treatment goals for glycemia, blood pressure, and
dyslipidemia. This framework is based on the work of
Blaum et al.,131 in which health status, defined by the
presence and number of comorbidities or impairments of
functional status, leads to the identification of three major
classes of older patients: (1) those who are relatively
healthy, (2) those with complex medical histories where
self-care may be difficult, and (3) those with a very signifi-
cant comorbid illness and functional impairment. The
three classes correspond with increasing levels of mortality
risk.131 The observation that there are three major classes
of older diabetic patients is supported by other research.132
Table 2. Additional Consensus Recommendations for Care of Older Adults with Diabetes
Screening for and prevention of diabetes
Screen older adults for prediabetes and diabetes according to ADA recommendations, if the patient will be likely to benefit from identification of
the condition/disease and subsequent intervention.
Implement lifestyle intervention for older adults with prediabetes who are able to participate and are likely to benefit from the
prevention of type 2 diabetes.
Management of diabetes
Encourage physical activity, even if not to optimal levels, and implement MNT using simple teaching strategies and community resources while
considering patient safety and preferences.
DSME/T in older adults should take into account sensory deficits, cognitive impairment, and different learning styles and teaching strategies and
should include caregivers.
In order to develop and update an individualized treatment plan, screen older adults periodically for cognitive dysfunction, functional status, and
fall risk, using simple tools such as those at http://www.hospitalmedicine.org/geriresource/toolbox/determine.htm.
Pharmacotherapy
Carefully choose antihyperglycemic therapies, considering polypharmacy. Avoid glyburide in older adult patients. Metformin can be used safely and
is the preferred initial therapy in many older adults with type 2 diabetes, but at reduced dose in those with stage III chronic kidney disease, and
avoid in those with stage IV or worse. Assess renal function using eGFR, not serum creatinine alone.
Assess patients for hypoglycemia regularly by asking the patient and caregiver about symptoms or signs and reviewing blood glucose logs. In
type 2 diabetic patients, hypoglycemia risk is linked more to treatment strategies than to achieved lower A1C (e.g., a patient with a low A1C on
metformin alone may be at considerably lower risk of hypoglycemia than a patient with a high A1C on insulin).
If recurrent or severe hypoglycemia occurs, strongly consider changing therapy and/or targets.
Assess the burden of treatment on older adult patients (caregivers), consider patient/caregiver preferences, and attempt to reduce treatment
complexity.
Management of older adults with diabetes in settings outside the home
The glycemic goals for hospitalized older adults with diabetes are usually similar to those for the general population. The use of SSI alone for
chronic glycemic management is discouraged in inpatient settings as well as in LTC facilities.
Transitions of older adults with diabetes (e.g., from home or LTC facility to hospital to postdischarge setting) are periods of high risk. Careful
medication reconciliation and written information regarding medication dosing and timing help to minimize risk for hyper- and hypoglycemia. Early
transition of diabetes care to an outpatient provider is important to modify drug therapy according to changes in clinical status.
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The framework is an attempt to balance the expected time
frame of benefit of interventions with anticipated life
expectancy. Table 2 provides additional consensus recom-
mendations beyond goals of treatment of glycemia, blood
pressure, and dyslipidemia.
HOW CAN GAPS IN THE EVIDENCE BEST BE
FILLED?
The exclusion of older, and especially frail older, partici-
pants from most traditional randomized controlled trials
of diabetes interventions has left us with large gaps in our
knowledge of how best to address diabetes in the age-
group with the highest prevalence rates. Future research
should allow and account for the complexity and heteroge-
neity of older adults. Studies will need to include patients
with multiple comorbidities, dependent living situations,
and geriatric syndromes in order to advance our knowl-
edge about these populations. Beyond broadening the
inclusion criteria for randomized controlled trials, we will
increasingly need sophisticated observational or compara-
tive effectiveness evidence from “real world” settings and
populations. Suggested research questions and topics are
listed in Table 3.
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Table 3. Consensus Recommendations for Research Questions About Diabetes in Older Adults
What specific cellular and molecular mechanisms define the interactions between aging and lifestyle factors that underlie the high rates of diabetes
in the older adult population? How can such mechanisms be used to develop effective intervention strategies?
How does aging affect the trajectories of development of macro- and microvascular complications over time?
What are the best interventions to prevent type 2 diabetes in older adults? How can evidence-based lifestyle intervention strategies be widely
implemented in the community in ways that maximize the participation of older adults?
More studies of the mechanisms of the link between diabetes and cognitive impairment should be conducted. Many diabetes trials that include
older adults should include the assessment of cognition as a covariate or outcome. Does treatment of hyperglycemia in general or via particular
strategies reduce the risk of diabetes-associated cognitive impairment? Is such cognitive impairment slowed or prevented by diabetes prevention
strategies?
What is the optimal level of blood pressure control in older adults with diabetes? What are the best treatment strategies?
Do specific diabetes interventions prevent or slow decline in functional status in older adults?
How can fall risk be reduced in older adults with diabetes?
Can we make it easier for clinicians to anticipate the expected lifetime benefits of interventions, such as decision support tools for life expectancy
embedded in electronic health records? What impact will formal use of prognostic information have on diabetes care and patient outcomes?
What aspects of patient-provider communication are most effective in shared decision-making with older patients and caregivers?
What are the ethical and patient preference concerns about de-intensifying therapy in older adults who are deemed unlikely to reap benefits from
aggressive therapy of diabetes and its comorbidities?
Comparative effectiveness studies of diabetes therapies in older adults should be undertaken. Does comparative effectiveness differ for older
compared with younger adults?
What are the health literacy/numeracy issues in this population, and how can they best be addressed?
What is the true incidence of hypoglycemia in older adults? How can it be recognized and reduced? What are the mechanisms of the bidirectional
association of severe hypoglycemia with cognitive impairment? Is the relationship of hypoglycemia to cardiovascular outcomes a direct cause/
effect, or is it more complex?
What is the impact of geriatric syndromes on the management of diabetes and on the risk for adverse treatment effects and poor outcomes?
What are significant race/ethnic disparities among older adults with diabetes, and what are the best approaches to addressing them?
What strategies are effective for increasing physical activity in older adults with diabetes? What are the effects of exercise on clinical and
psychosocial outcomes?
Is there evidence that intentional weight loss is beneficial in overweight older adults with diabetes?
What are the best strategies for DSME/S in older adults? What are the roles of technology, group versus individual education, and support by
community resources?
What are the unique stressors of caregivers of these older adults with diabetes, and how can they be addressed?
What are the mechanisms of the impact of diabetes and specific therapies on bone health?
What is the expected time frame of benefit of diabetes interventions, including complications screening and care? Such studies will likely require
the use of longitudinal studies and registries rather than randomized controlled trials.
What is the appropriate frequency and cost-effectiveness of self-monitored blood glucose in heterogeneous older adults with diabetes?
Studies of older patients in hospitals and LTC facilities are greatly needed. What are appropriate treatment goals and strategies for these
populations? How can transitions of care (e.g., between hospital and LTC facility) be optimized to maximize patient safety? Will system changes,
such as accountable care organizations, improve outcomes in vulnerable older adults?
DSME/S = diabetes self-management education/support; LTC = long-term care.
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